All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 EGFR mutation Ex19del EGFR mutation L858R Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES previous systemic treatment (%) previous systemic treatment NO (%) smoker (current or former) smoker (never) stage I stage II stage IIIa
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), gene alteration target therapy vs. non active control, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ADAURA (stage II-IIIA), 2020 0.40 [0.09; 1.80]
0.40 [0.09 ; 1.80 ] ADAURA (stage II-IIIA), 2020 1 0% 682 NA not evaluable RFS/DFSdetailed results ADAURA (Stage IB to IIIA), 2020 0.20 [0.14; 0.29]
0.20 [0.14 ; 0.29 ] ADAURA (Stage IB to IIIA), 2020 1 0% 682 NA not evaluable events or deaths (EFS)detailed results ADAURA (stage II-IIIA), 2020 0.17 [0.11; 0.26]
0.17 [0.11 ; 0.26 ] ADAURA (stage II-IIIA), 2020 1 0% 682 NA not evaluable AE (any grade)detailed results ADAURA (Stage IB to IIIA), 2020 4.97 [2.28; 10.85]
4.97 [2.28 ; 10.85 ] ADAURA (Stage IB to IIIA), 2020 1 0% 680 NA not evaluable AE leading to death (grade 5)detailed results ADAURA (Stage IB to IIIA), 2020 0.51 [0.02; 15.20]
0.51 [0.02 ; 15.20 ] ADAURA (Stage IB to IIIA), 2020 1 0% 680 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results ADAURA (Stage IB to IIIA), 2020 4.11 [2.01; 8.40]
4.11 [2.01 ; 8.40 ] ADAURA (Stage IB to IIIA), 2020 1 0% 680 NA not evaluable Cough AE (grade 3-4)detailed results ADAURA (Stage IB to IIIA), 2020 1.02 [0.02; 51.45]
1.02 [0.02 ; 51.45 ] ADAURA (Stage IB to IIIA), 2020 1 0% 680 NA not evaluable Decreased appetite AE (grade 3-4)detailed results ADAURA (Stage IB to IIIA), 2020 4.09 [0.18; 91.02]
4.09 [0.18 ; 91.02 ] ADAURA (Stage IB to IIIA), 2020 1 0% 680 NA not evaluable Dermatitis acneiform AE (grade 3-4)detailed results ADAURA (Stage IB to IIIA), 2020 1.02 [0.02; 51.45]
1.02 [0.02 ; 51.45 ] ADAURA (Stage IB to IIIA), 2020 1 0% 680 NA not evaluable Diarrhoea AE (grade 3-4)detailed results ADAURA (Stage IB to IIIA), 2020 8.32 [1.03; 66.86]
8.32 [1.03 ; 66.86 ] ADAURA (Stage IB to IIIA), 2020 1 0% 680 NA not evaluable Dry skin AE (grade 3-4)detailed results ADAURA (Stage IB to IIIA), 2020 2.04 [0.07; 60.97]
2.04 [0.07 ; 60.97 ] ADAURA (Stage IB to IIIA), 2020 1 0% 680 NA not evaluable Pruritus AE (grade 3-4)detailed results ADAURA (Stage IB to IIIA), 2020 1.02 [0.02; 51.45]
1.02 [0.02 ; 51.45 ] ADAURA (Stage IB to IIIA), 2020 1 0% 680 NA not evaluable Stomatitis AE (grade 3-4)detailed results ADAURA (Stage IB to IIIA), 2020 12.42 [0.69; 223.20]
12.42 [0.69 ; 223.20 ] ADAURA (Stage IB to IIIA), 2020 1 0% 680 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 00:07 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 1413,435,434,1514,1515,474,1513,1390,714,423,424,425,562,426,1472,1400,1396,1468,431,1392,1391,1415,1416,1417,1493,1397,1383,1399,1426,1398,1387,1106,1108,1107,1393,1394,1402,1388,1389,1386,1384,1522,1385,1512,1511,1454
